PTK2 and neoplasm: In summary, the combined treatment would allow to attack the tumor cells with an anti-HER2 therapy but also block its intracellular activation by inducing FAK translocation to the nucleus, thus deactivating the signaling pathway at two different sites and eventually diminishing cellular migration.